Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Summary

This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.

Timeline

Start

2020-10-23

Primary completion

2022-09-20

Completion

2022-09-20

Drugs

Indications